#USA #Singapore #Emerald Clinical Trials #Glenn Kerkhof #Mary Gunn

Emerald Clinical Trials Announces Leadership Change

On July 31, 2025, Emerald Clinical Trials, a prominent global organization in clinical research, confirmed the departure of its CEO, Mary Gunn. This sudden change has led to the appointment of Glenn Kerkhof as the interim CEO. Kerkhof, who has a long history with the company, is expected to guide Emerald through a crucial transition phase.

The Board of Directors acted swiftly in requesting Kerkhof to step in temporarily, assuring continuity and operational effectiveness. Sean Carney, Chairman of the Board, expressed appreciation for Gunn's contributions to the organization. He stated, "Emerald Clinical Trials is a leading CRO with global capabilities. With Glenn's interim leadership, we are confident in maintaining our momentum and fulfilling our commitments to clients."

Kerkhof brings over 30 years of experience in the clinical research and pharmaceutical sectors to his new role. His previous positions include serving as CEO of Chiltern, where he skillfully directed the company through significant international growth. Additionally, he played a key role as Executive Chairman at George Clinical (now Emerald Clinical Trials), significantly contributing to the company’s expansion in Asia.

In taking on this new challenge, Kerkhof emphasized the strengths of Emerald Clinical. "Our therapeutic focus, scientific expertise, and close partnerships with clients set us apart," he noted. He outlined his priorities during this transition: ensuring a smooth handover, delivering reliable client services, and supporting the global teams. Kerkhof aims to maintain growth momentum while steering the organization with clarity and purpose.

Emerald Clinical Trials is recognized as a leading clinical research organization with a global reach, serving over 100 biotechnology companies and six of the world's ten largest pharmaceutical firms. Headquartered in Singapore, the company harnesses practical expertise and scientific advancements to deliver comprehensive clinical trial services, offering solutions across all stages of research. For further information, visit Emerald Clinical Trials.

As the leadership change unfolds, both employees and clients of Emerald Clinical Trials will be closely watching how the organization adapts and evolves under Kerkhof's direction. The Board is now actively engaged in finding a permanent CEO to ensure the continued success and growth of the organization, emphasizing the importance of stability during this transitional phase.